Minerva reports Q2 2026 results, confirms C19 trial timeline for roluperidone

Minerva Neurosciences reported second quarter 2026 financial results and business updates on August 7, 2026. The company said its confirmatory Phase 3 trial of roluperidone, known as the C19 Study, is designed to enroll 380 patients across roughly 40 clinical sites worldwide, spanning the United States and multiple European countries.¹

The trial has two parts. Phase A will test roluperidone at 64 mg against placebo to confirm its effect on primary negative symptoms after 12 weeks.¹ Phase B will assess longer-term relapse of positive symptoms comparing roluperidone to commonly used antipsychotics over an additional 52 weeks, with topline data expected in the second half of 2028.¹ Phase A topline efficacy data are expected in the second half of 2027, the company said.

Minerva also said it expanded its Scientific Advisory Board. The board was first announced on June 1, 2026, with eight members experienced in psychiatry and neuroscience research advising on the roluperidone trial and potential future pipeline programs.¹ Three more members were added, bringing the total to eleven, including Christoph Correll, Stefan Leucht, and Michael Sand.¹

On finances, the company reported cash, cash equivalents, marketable securities and restricted cash of approximately $75.4 million at June 30, 2026, down from $82.4 million at December 31, 2025.¹ R&D expense rose in the quarter, which the company attributed to costs tied to the C19 trial along with higher compensation expense.¹ The company also recorded a non-cash gain of $27.6 million in the quarter from the change in fair value of its warrant liability, tied to warrants issued in the October 2025 private placement.¹